Thyrotropin releasing hormone (TRH) suppresses stress induced eating

Thyrotropin-Releasing Hormone and Food Intake in Mammals: An Update

Thyrotropin-releasing hormone (TRH; pGlu-His-Pro-NH2) is an intercellular signal produced mainly by neurons. Among the multiple pharmacological effects of TRH, that on food intake is not well understood. We review studies demonstrating that peripheral injection of TRH generally produces a transient anorexic effect, discuss the pathways that might initiate this effect, and explain its short half-life. In addition, central administration of TRH can produce anorexic or orexigenic effects, depending on the site of injection, that are likely due to interaction with TRH receptor 1. Anorexic effects are most notable when TRH is injected into the hypothalamus and the nucleus accumbens, while the orexigenic effect has only been detected by injection into the brain stem. Functional evidence points to TRH neurons that are prime candidate vectors for TRH action on food intake. These include the caudal raphe nuclei projecting to the dorsal motor nucleus of the vagus, and possibly TRH neurons from the tuberal lateral hypothalamus projecting to the tuberomammillary nuclei. For other TRH neurons, the anatomical or physiological context and impact of TRH in each synaptic domain are still poorly understood. The manipulation of TRH expression in well-defined neuron types will facilitate the discovery of its role in food intake control in each anatomical scene.

Age-related ciliopathy: Obesogenic shortening of melanocortin-4 receptor-bearing neuronal primary cilia

Obesity is often associated with aging. However, the mechanism of age-related obesity is unknown. The melanocortin-4 receptor (MC4R) mediates leptin-melanocortin anti-obesity signaling in the hypothalamus. Here, we discovered that MC4R-bearing primary cilia of hypothalamic neurons progressively shorten with age in rats, correlating with age-dependent metabolic decline and increased adiposity. This "age-related ciliopathy" is promoted by overnutrition-induced upregulation of leptin-melanocortin signaling and inhibited or reversed by dietary restriction or the knockdown of ciliogenesis-associated kinase 1 (CILK1). Forced shortening of MC4R-bearing cilia in hypothalamic neurons by genetic approaches impaired neuronal sensitivity to melanocortin and resulted in decreased brown fat thermogenesis and energy expenditure and increased appetite, finally developing obesity and leptin resistance. Therefore, despite its acute anti-obesity effect, chronic leptin-melanocortin signaling increases susceptibility to obesity by promoting the age-related shortening of MC4R-bearing cilia. This study provides a crucial mechanism for age-related obesity, which increases the risk of metabolic syndrome.

Anorexigenic neuropeptides as anti-obesity and neuroprotective agents: exploring the neuroprotective effects of anorexigenic neuropeptides

Since 1975, the incidence of obesity has increased to epidemic proportions, and the number of patients with obesity has quadrupled. Obesity is a major risk factor for developing other serious diseases, such as type 2 diabetes mellitus, hypertension, and cardiovascular diseases. Recent epidemiologic studies have defined obesity as a risk factor for the development of neurodegenerative diseases, such as Alzheimer's disease (AD) and other types of dementia. Despite all these serious comorbidities associated with obesity, there is still a lack of effective antiobesity treatment. Promising candidates for the treatment of obesity are anorexigenic neuropeptides, which are peptides produced by neurons in brain areas implicated in food intake regulation, such as the hypothalamus or the brainstem. These peptides efficiently reduce food intake and body weight. Moreover, because of the proven interconnection between obesity and the risk of developing AD, the potential neuroprotective effects of these two agents in animal models of neurodegeneration have been examined. The objective of this review was to explore anorexigenic neuropeptides produced and acting within the brain, emphasizing their potential not only for the treatment of obesity but also for the treatment of neurodegenerative disorders.

Involvement of the Dorsal Vagal Complex in Alcohol-Related Behaviors

The neurobiological mechanisms that regulate the development and maintenance of alcohol use disorder (AUD) are complex and involve a wide variety of within and between systems neuroadaptations. While classic reward, preoccupation, and withdrawal neurocircuits have been heavily studied in terms of AUD, viable treatment targets from this established literature have not proven clinically effective as of yet. Therefore, examination of additional neurocircuitries not classically studied in the context of AUD may provide novel therapeutic targets. Recent studies demonstrate that various neuropeptides systems are important modulators of alcohol reward, seeking, and intake behaviors. This includes neurocircuitry within the dorsal vagal complex (DVC), which is involved in the control of the autonomic nervous system, control of intake of natural rewards like food, and acts as a relay of interoceptive sensory information via interactions of numerous gut-brain peptides and neurotransmitter systems with DVC projections to central and peripheral targets. DVC neuron subtypes produce a variety of neuropeptides and transmitters and project to target brain regions critical for reward such as the mesolimbic dopamine system as well as other limbic areas important for the negative reinforcing and aversive properties of alcohol withdrawal such as the extended amygdala. This suggests the DVC may play a role in the modulation of various aspects of AUD. This review summarizes the current literature on neurotransmitters and neuropeptides systems in the DVC (e.g., norepinephrine, glucagon-like peptide 1, neurotensin, cholecystokinin, thyrotropin-releasing hormone), and their potential relevance to alcohol-related behaviors in humans and rodent models for AUD research. A better understanding of the role of the DVC in modulating alcohol related behaviors may lead to the elucidation of novel therapeutic targets for drug development in AUD.

Neuroendocrine control of appetite and metabolism

Body homeostasis is predominantly controlled by hormones secreted by endocrine organs. The central nervous system contains several important endocrine structures, including the hypothalamic-pituitary axis. Conventionally, neurohormones released by the hypothalamus and the pituitary gland (hypophysis) have received much attention owing to the unique functions of the end hormones released by their target peripheral organs (e.g., glucocorticoids released by the adrenal glands). Recent advances in mouse genetics have revealed several important metabolic functions of hypothalamic neurohormone-expressing cells, many of which are not readily explained by the action of the corresponding classical downstream hormones. Notably, the newly identified functions are better explained by the action of conventional neurotransmitters (e.g., glutamate and GABA) that constitute a neuronal circuit. In this review, we discuss the regulation of appetite and metabolism by hypothalamic neurohormone-expressing cells, with a focus on the distinct contributions of neurohormones and neurotransmitters released by these neurons.

Prepuberal light phase feeding induces neuroendocrine alterations in adult rats

Feeding patterns are important factors in obesity evolvement. Time-restricted feeding schedules (tRF) during resting phase change energy homeostasis regulation, disrupting the circadian release of metabolism-regulating hormones, such as leptin, insulin and corticosterone and promoting body weight gain. Thyroid (HPT) and adrenal (HPA) axes exhibit a circadian regulation and are involved in energy expenditure, thus studying their parameters in tRF paradigms will elucidate their role in energy homeostasis impairments under such conditions. As tRF in young animals is poorly studied, we subjected prepuberal rats to a tRF either in light (LPF) or in darkness phase (DPF) and analyzed HPT and HPA response when they reach adulthood, as well as their arcuate (ARC) and paraventricular (PVN) hypothalamic nuclei neurons' sensitivity to leptin in subsets of 10-week-old animals after fasting and with i.p. leptin treatment. LPF group showed high body weight and food intake, along with increased visceral fat pads, corticosterone, leptin and insulin serum levels, whereas circulating T₄ decreased. HPA axis hyperactivity was demonstrated by their high PVN Crf mRNA expression; the blunted activity of HPT axis, by the decreased hypophysiotropic PVN Trh mRNA expression. Trh impaired expression to the positive energy balance in LPF, accounted for their ARC leptin resistance, evinced by an increased Npy and Socs3 mRNA expression. We concluded that the hyperphagia of prepuberal LPF animals could account for the HPA axis hyperactivity and for the HPT blocked function due to the altered ARC leptin signaling and impaired NPY regulation on PVN TRH neurons.

Hypothalamic neuronal histamine mediates the thyrotropin-releasing hormone-induced suppression of food intake

We examined the involvement of thyrotropin-releasing hormone (TRH) and TRH type 1 and 2 receptors (TRH-R1 and TRH-R2, respectively) in the regulation of hypothalamic neuronal histamine. Infusion of 100 nmol TRH into the rat third cerebroventricle (3vt) significantly decreased food intake (p < 0.05) compared to controls infused with phosphate- buffered saline. This TRH-induced suppression of food intake was attenuated partially in histamine-depleted rats pre-treated with alpha-fluoromethylhistidine (a specific suicide inhibitor of histidine decarboxylase) and in mice with targeted disruption of histamine H1 receptors. Infusion of TRH into the 3vt increased histamine turnover as assessed by pargyline-induced accumulation of tele-methylhistamine (t-MH, a major metabolite of neuronal histamine in the brain) in the tuberomammillary nucleus (TMN), the paraventricular nucleus, and the ventromedial hypothalamic nucleus in rats. In addition, TRH-induced decrease of food intake and increase of histamine turnover were in a dose-dependent manner. Microinfusion of TRH into the TMN increased t-MH content, histidine decarboxylase (HDC) activity and expression of HDC mRNA in the TMN. Immunohistochemical analysis revealed that TRH-R2, but not TRH-R1, was expressed within the cell bodies of histaminergic neurons in the TMN of rats. These results indicate that hypothalamic neuronal histamine mediates the TRH-induced suppression of feeding behavior.

Our journey with neuropeptide Y: effects on ingestive behaviors and energy expenditure

Clark and colleagues first described the robust orexigenic effects of neuropeptide Y (NPY) in 1984. Our group as well as Stanley et al. confirmed these effects in the same year. During the next 20 years, we investigated the effects of NPY on diet preferences, opioid-related feeding, distributed neural feeding networks, energy metabolism, motivation and discriminative stimulus effects. These data together with data from other laboratories indicate that NPY increases feeding, even when rats work for food; that NPY decreases energy expenditure, particularly by altering thermogenesis; and that NPY's effects on energy metabolism are mediated by a widely distributed neural network involving other neuroregulators known to be involved in energy regulation.

Neuropeptides, food intake and body weight regulation: a hypothalamic focus

Energy homeostasis is controlled by a complex neuroendocrine system consisting of peripheral signals like leptin and central signals, in particular, neuropeptides. Several neuropeptides with anorexigenic (POMC, CART, and CRH) as well as orexigenic (NPY, AgRP, and MCH) actions are involved in this complex (partly redundant) controlling system. Starvation as well as overfeeding lead to changes in expression levels of these neuropeptides, which act downstream of leptin, resulting in a physiological response. In this review the role of several anorexigenic and orexigenic (hypothalamic) neuropeptides on food intake and body weight regulation is summarized.

Uptake of cyclic dipeptide by PEPT1 in Caco-2 cells: phenolic hydroxyl group of substrate enhances affinity for PEPT1

Uptake of cyclic dipeptides by H+/oligopeptide cotransporter (PEPT1) was studied in monolayers of the human intestinal cell line, Caco-2. The cyclic dipeptides studied were cyclic glycylphenylalanine (cyclo(Gly-Phe)), cyclic phenylalanylserine (cyclo(Phe-Ser)), cyclic seryltyrosine (cyclo(Ser-Tyr)) and cyclic glycyltyrosine (cyclo(Gly-Tyr)). These molecules have both peptide bonds and aromatic rings, and are similar in structure to cephalexin and cephadroxil, which are transported by PEPT1. Cellular uptake of these cyclic dipeptides was pH dependent, and was inhibited by the addition of PEPT1 substrates such as glycylsarcosine, indicating PEPT1-mediated transport. Michaelis constants (Km) for these cyclic dipeptides were cyclo(Ser-Tyr) < cyclo(Phe-Ser), and cyclo(Gly-Tyr) < cyclo(Gly-Phe), indicating that tyrosine possessing phenol moiety has higher affinity for PEPT1 than phenylalanine possessing benzen moiety. The Km for cephadroxil possessing phenol moiety was reportedly lower than that for cephalexin possessing benzen moiety. Therefore, it was concluded that the phenolic hydroxyl group of the substrate may enhance affinity for PEPT1.

Thyrotropin releasing hormone decreases alcohol intake and preference in rats

Thyrotropin releasing hormone (TRH) has been reported to reduce stress- and deprivation-induced eating, hypothetically by induction of satiation. Early work demonstrated thyroid extracts reduced alcohol intake, and recent research shows a TRH analog specifically inhibits alcohol preference. We determined whether parenteral administration of TRH reduces alcohol consumption and choice in a manner consistent with a satiation effect. Water-restricted ad lib fed female and male rats (n = 12) were given access to 5% w/v ethanol 0 or 30 minutes after intraperitoneal (i.p.) injection of TRH. TRH (20-40 mg/kg) inhibited alcohol intake only if injected immediately before alcohol access. Inhibition of alcohol intake was reliably accompanied by increased production of fecal boli but not by reliably decreased food intake. Rats given a choice of 2% w/v ethanol and water decreased alcohol preference after TRH (20 mg/kg) but did not reduce total fluid intake. Results are partially consistent with the hypothesis of TRH as one of several functional elements in the integrative neuropeptide control of alcohol consumption via short-term satiation.

Intestinal absorption of stable cyclic dipeptides by the oligopeptide transporter in rat

Intestinal absorption of four cyclic dipeptides was studied in the everted small intestine of the rat. Cyclic seryltyrosine (cyclo(Ser-Tyr)) was stable enough to be transported whereas linear seryltyrosine was not. The absorption clearance of cyclo(Ser-Tyr) was concentration-dependent, and for cyclo(Ser-Tyr) at 125 microM decreased in the presence of glycylsarcosine (10 mM) or cephalexin (10 mM), which were reported to be absorbed by oligopeptide transporter. The absorption clearance was also reduced at 4 degrees C and in the presence of 1 mM dinitrophenol. Kinetic analysis of cyclo(Ser-Tyr) absorption showed that Km and Vmax were 19.8 microM and 0.295 nmol min(-1) cm(-1), respectively. It was also suggested that cyclic aspartylphenylalanine and cyclic histidylphenylalanine were absorbed by oligopeptide transporters, but cyclic histidylproline was not. The absorption clearance of cyclo(Ser-Tyr) in the control was much higher than the value of the correlation line representing a plot of passive transport (which was obtained from the absorption clearance of cyclic peptides in the presence of glycylsarcosine (10 mM)) against hydrophobicity (oil-water partition coefficient). These results indicate that cyclo(Ser-Tyr) is absorbed by the oligopeptide transporter.

Thyrotropin-releasing hormone (TRH) has independent excitatory and modulatory actions on lamina IX neurons of lumbosacral spinal cord slices from adult rats

Coronal and horizontal slices of the lumbar and sacral spinal cord, respectively, of ovariectomized adult rats, either treated with estrogen (OVX+E) or untreated (OVX), were used to test the neuronal actions of TRH and its metabolite, cyclo(His-Pro) (or cHP). Both coronal slices, which possess only short stumps of ventral roots (VRs), and horizontal slices, in which long sections of VRs were preserved, were used for extracellular recording of single motor and other types of neurons. Methodological comparisons between these two types of slices showed that the length of VRs preserved had no significant effect on the characteristics of motoneurons (MNs). In coronal slices, MNs in medial and lateral lamina IX (MNM and MNL, respectively) were identified by antidromic activation. Of these lumbar MNs, estrogen treatment lowered the antidromic activation threshold for MNM but not MNL. Because MNM innervate the back muscles crucial for the execution of the estrogen-dependent lordosis, the observed estrogen effect may contribute to the hormone's induction of the sexual behavior. The recorded MNs and other types of neurons were subjected to bath applications of TRH, cHP, and neurotransmitters. TRH was found to be capable of evoking an early, shorter-lasting neuronal excitation and/or a late, longer-lasting modulation of neuronal responses to transmitters. Each neuronal action could occur with or without the other, and the occurrence of the excitation did not affect the probability of whether a modulation would occur later. The modulatory, but not the excitatory, action appeared to be shared by cHP, because cHP could also modulate neuronal responses in similar, if not identical, ways as TRH did, but could neither stimulate neurons nor mimic TRH in desensitizing TRH-evoked excitation. The modulatory actions of the two peptides were not affected by estrogen. Although the excitatory action was desensitized by repeated TRH applications, the modulatory action did not appear to be attenuated but instead was often enhanced by repeated administrations of TRH and/or cHP. These results, together with the essentially identical findings from our previous study on hypothalamic neurons, indicate that the excitatory and the modulatory actions of TRH are independent of each other and, hence, are mediated by different subcellular mechanisms.

Growth hormone-regulatory peptides (GHRH and somatostatin) and feeding: a model for the integration of central and peripheral function

The present paper provides an overview of findings that implicate growth hormone-releasing hormone (GHRH) and somatostatin (SS), the two peptides that regulate growth hormone secretion, in the central regulation of feeding. Evidence is presented that GHRH and SS increase food intake, in the rat, via a common centrally mediated mechanism involving the suprachiasmatic nucleus. Food intake is increased by increasing motivation to eat as evidenced by facilitation of operant behavior. Macronutrient-choice studies indicate that GHRH (and possibly SS) selectively facilitate protein consumption. Time of day is also important, with evidence that endogenous GHRH and SS-induced feeding is most strong in the early nocturnal period. GHRH and SS, together with other nutrient-specific signals, such as neuropeptide Y, noradrenaline and galanin, may determine the circadian expression of food intake in animals. Other behavioral and physiological effects of these peptides, both central and peripheral, are reviewed in the context of a possible mechanism by which these peptides integrate diverse, but complimentary, central and peripheral functions related to nutrition, metabolism and growth.

The lateral hypothalamic area revisited: neuroanatomy, body weight regulation, neuroendocrinology and metabolism

This article reviews findings that have accumulated since the original description of the syndrome that follows destruction of the lateral hypothalamic area (LHA). These data comprise the areas of neuroanatomy, body weight regulation, neuroendocrinology, neurochemistry, and intermediary metabolism. Neurons in the LHA are the largest in the hypothalamus, and are topographically well organized. The LHA belongs to the parasympathetic area of the hypothalamus, and connects with all major parts of the brain and the major hypothalamic nuclei. Rats with LHA lesions regulate their body weight set point in a primary manner and not because of destruction of a "feeding center". The lower body weight is not due to finickiness. In the early stages of the syndrome, catabolism and running activity are enhanced, and so is the activity of the sympathetic nervous system (SNS) as shown by increased norepinephrine excretion that normalizes one mo later. The LHA plays a role in the feedback control of body weight regulation different from ventromedial (VMN) and dorsomedial (DMN). Tissue preparations from the LHA promote glucose utilization and insulin release. Although it does not belong to the classical hypothysiotropic area of the hypothalamus, the LHA does affect neuroendocrine secretions. No plasma data on growth hormone are available following electrolytic lesions LHA but electrical stimulation fails to elicit GH secretion. Nevertheless, antiserum raised against the 1-37 fragment of human GHRF stains numerous perikarya in the dorsolateral LHA. The plasma circadian corticosterone rhythm is disrupted in LHA lesioned rats, but this is unlikely due to destruction of intrinsic oscillators. Stimulation studies show a profound role of the LHA in glucose metabolism (glycolysis, glycogenesis, gluconeogenesis), this mechanism being cholinergic. Its role in lipolysis appears not to be critical. In general, stimulation of the VMN elicits opposite effects. Lesion studies in rats show altered in vitro glucose carbon incorporation into several tissue fractions both a few days, and one mo after lesion production. Several of these changes may be due to the reduced food intake, others appear to be due to a "true" lesion effect.

The effects of the TRH metabolite cyclo(His-Pro) and its analogs on feeding

Cyclo(His-Pro), or cHP, is a putative metabolite of thyrotropin-releasing hormone (TRH), and, like TRH, can inhibit food intake but requires higher doses. In attempts to improve the anorectic effects of cHP through modification of its structure, a number of its analogs were synthesized. These analogs or cHP itself were administered to rats either by intracerebroventricular (ICV) infusion or systemic injection, and their effects on food intake were measured. None of the synthetic analogs was more potent than cHP, although several analogs demonstrated comparable potencies to the parent compound. Interestingly, one cHP analog reversed the suppressive effect and stimulated feeding. This reversal, as well as the preservation of the anorectic effect by some but not all the analogs, suggests that the cHP effect on feeding does require specific structural features.

Cyclo(His-Pro) potentiates the reduction of food intake induced by amphetamine, fenfluramine, or serotonin

Electrophysiological and pharmacological evidence suggests that cyclo(His-Pro) (cHP) could reduce food intake by modulating the actions of relevant neurotransmitters. We tested this hypothesis by giving rats a combination of cHP or its analogs centrally and an anorectic, amphetamine or fenfluramine, systemically. Compared to saline control, cHP at doses too low to affect food intake by itself significantly potentiated the reduction of food intake by amphetamine. This potentiation is thought to be due to cHP modulation of norepinephrine (NE) action, because at the low dose used amphetamine acts mainly through NE to inhibit food intake. The modulation has specific requirements for cHP structure, since it was mimicked by one but not two other analogs tested. The anorectic effect of fenfluramine was also potentiated and prolonged by cHP at a dose not effective by itself. Since fenfluramine is known to act by increasing brain serotonin (5-HT), the potentiation was apparently a result of an interaction between cHP and 5-HT effects. To examine this interaction more directly, we administered both cHP and 5-HT centrally. Again, cHP potentiated the reduction of food intake caused by 5-HT. Thus the neuromodulation of feeding-relevant neurotransmitter effects, following NE and 5-HT, is probably a mechanism by which cHP reduces food intake.

Acetylation alters the feeding response to MSH and beta-endorphin

The effects on food intake of the N-acetylation of MSH and beta-endorphin have been examined following their injection into the third ventricle. Desacetyl-MSH and alpha-MSH were injected into fasted rats, and beta-endorphin and N-acetyl-beta-endorphin into fed rats. Desacetyl-MSH had no effect on food intake following ICV injection into food-deprived rats at any dose between 100 and 2500 pmoles. Alpha-MSH, the N-acetylated form of MSH, on the other hand, showed a highly significant inhibition of food intake in food-deprived rats with doses of 100 and 250 pmoles but no effect with the higher doses. With beta-endorphin, there was a dose-related biphasic effect. One hour after injection of beta-endorphin (2500 pmole) food intake was inhibited whereas the lowest dose, 100 pmole, significantly stimulated it. By 3 hours, the 2 lowest doses of beta-endorphin both significantly stimulated food intake, but the highest dose remained inhibitory. By 6 hours all doses of beta-endorphin stimulated food intake compared to the vehicle-treated animals. In contrast, N-acetylation of beta-endorphin eliminated all effects on food intake following injection into the third ventricle. These data suggest that N-acetylation of products formed by the processing of POMC can markedly alter their biological properties.

Physiologic approaches to the control of obesity

Morbid obesity is a major health problem in this country and throughout the world. In addition to its social stigma (in the western world), obesity exacerbates several disease states such as diabetes, hypertension, cardiac disease and restrictive lung disease. When effective medical treatment of obesity becomes available, it will depend in part upon understanding the physiologic factors that control satiety. This review summarizes the information available on brain and gut control mechanisms of satiety. Brain nuclei located in the lateral hypothalamus, ventromedial hypothalamus, and other paraventricular areas are the sites of action for potent neuropeptides, such as cholecystokinin (CCK) and neuropeptide Y, that appear to regulate feeding. Exogenous CCK has been used clinically to decrease meal size in obese patients. The sites of the satiety cascade that are most often manipulated are the gastric and intestinal phases. Physiologic gastric distension is a potent inhibitor of feeding, whereas the intermeal interval may be regulated by intestinal signals released by food in the gut. Jejunal-ileal bypass has fallen from favor and has been replaced by gastric restrictive procedures that create a small proximal gastric pouch that empties into the small bowel (gastric bypass) or the distal stomach (gastroplasty). These operations rely partially on their ability to produce gastric distension in the proximal gastric pouch at an early stage during a meal. Thus, failure results if the pouch compensates by distending or if the stoma widens with subsequent loss of slow emptying. Improved medical and surgical treatment will be designed to intervene at specific sites of the satiety cascade as knowledge of the physiologic control mechanisms of satiety increases.

Re-evaluation of histidyl-proline diketopiperazine [cyclo(His-Pro)] effects on food intake in the rat

Histidyl-proline diketopiperazine [cyclo(His-Pro)], a metabolite of thyrotropin releasing hormone (TRH), has been reported to decrease food intake of rats in a variety of feeding models following intracerebroventricular (ICV) injection. We have re-evaluated the anorectic effects of cyclo(His-Pro) on food deprivation-induced and spontaneous feeding. When injected ICV at the end of the light period into ad lib fed rats, neither the naturally occurring cyclo(L-His-L-Pro) isomer (14 to 1000 nmole/rat) nor any of the four cyclo(D,L-His-D,L-Pro) stereoisomers (100 nmole/rat) significantly suppressed food intake at any hour for up to 12- or 24-hr post-injection. Bombesin (0.6 nmole/rat ICV) decreased food intake in the same model by up to 86% with anorexia still apparent 15-hr post-injection (71%, p less than 0.001). In two food deprivation-induced feeding models, cyclo(L-His-L-Pro) (100 and 1000 nmole/rat ICV) did not cause anorexia while TRH (10 and 1000 nmole/rat ICV) maximally suppressed food intake by 74% (p less than 0.02) and 50% (p less than 0.01). Occasional transient increases of food consumption were observed in cyclo(His-Pro)-treated rats during both spontaneous and induced feeding. Cyclo(L-His-L-Pro) was also without effect on food intake when intraperitoneally administered at 12.5 and 30 mumole/kg to schedule fed rats. TRH at 30 mumole/kg IP transiently suppressed food intake of schedule fed rats (p less than 0.005). These findings indicate that cyclo(His-Pro) does not exhibit anorectic activity in the rat and cast doubt on the concept that TRH-induced anorexia results from conversion of TRH to an active cyclo(His-Pro) metabolite.

Neuropeptides TRH and cyclo(His-Pro) share neuromodulatory, but not stimulatory, action on hypothalamic neurons in vitro: implication for the regulation of feeding

Electrical activity of neurons in rat hypothalamic ventromedial nucleus was recorded in tissue slices, to investigate central neural mechanisms underlying reduction of food intake caused by TRH and its metabolite, cyclo(His-Pro) [cHP]. Application of TRH had two actions: stimulation of neuronal activity, which was desensitized on closely repeated applications; and modulation of neuronal responses to neurotransmitters, even in the absence of the stimulatory action. The neuromodulatory but not the direct stimulatory action could also be achieved by cHP. The neuromodulatory action is more likely to be a neural mechanism underlying the inhibition of feeding, while other biological functions, unique to TRH, may depend on direct stimulation. In this way, TRH could achieve different biological results through different modes of action on hypothalamic neurons.

Experimental manipulations of eating: advances in animal models for studying anorectic agents

The material set out in this text has been designed to show the wide range of procedures which have the capacity to modify eating behavior--to produce hyper- or hypophagia, to alter the profile of eating patterns, or to adjust dietary preferences and selection. Accordingly, in investigating anorectic drugs it seems necessary to observe the effects of drug actions in a variety of experimental models. This strategy will provide a more complete description of the effect of a drug, will throw light on the mechanism of action, and will provide a more realistic base for predicting the effects of drugs in man.

Long-term effects of TRH administration on food intake and body weight in the rat

The effect of long-term TRH administration through drinking water (0.2 mg/ml) on food and water intake and body weight has been studied in three groups of female rats: (1) thyroidectomized, (2) thyroidectomized receiving daily 250 micrograms/kg of L-T4, (3) sham-operated. Treatment with oral TRH for 30 days decreased body weight and increased food intake in sham-operated rats. No TRH effects on body weight or food consumption were observed in either of the other groups of thyroidectomized rats. TRH administration increased circulating T3 levels in sham-operated animals, but had no effects in either hypo- or hyperthyroid, thyroidectomized rats. It can be concluded that the TRH-induced increase on food intake is mediated through the pituitary-thyroid axis.

Intracerebroventricular injection of a TRH analogue, gamma-butyrolactone-gamma-carbonyl-L-histidyl-prolinamide, induces gastric lesions and gastric acid stimulation in rats

The effects of TRH and its biologically stable analogue, gamma-butyrolactone-gamma-carbonyl-L-histidyl-L-prolinamide (DN-1417), on gastric mucosa and acid secretion were examined in rats. Intracerebroventricular (ICV) injection of DN-1417 (0.1-10 micrograms) caused a dose-dependent gastric lesion in the corpus and antrum 6 h after administration. The gastric lesions produced by 1 microgram of DN-1417 were more severe than those produced by ICV TRH (10 micrograms), intravenous DN-1417 (200 micrograms) and stress. Although the lesion-generating effect of TRH (10 micrograms) tended to be reduced 6 h after the injection, that of DN-1417 (1 microgram) was sustained during 6 h. Atropine (0.1 and 1 mg/kg s.c.) inhibited DN-1417-induced gastric lesions in a dose-related manner while sulpiride (10 and 30 mg/kg s.c.), haloperidol (1 mg/kg i.p.), phentolamine (1 and 5 mg/kg s.c.) and yohimbine (5 mg/kg s.c.) did not prevent the lesions. ICV DN-1417 also stimulated basal gastric acid secretion and the effect was stronger and longer-lasting than that of TRH. Atropine (0.1 mg/kg s.c.) stopped DN-1417-stimulated gastric acid secretion. In conclusion, the possibility that TRH may be involved in the CNS modulation of gastric mucosal integrity deserves further attention. The enhanced potency of action of DN-1417 over TRH could make ICV injection of this peptide a useful tool for inducing centrally-mediated gastric lesions in rats.

Peptides as central regulators of feeding

During the past decade there has been an increased awareness of the role peptides play as neuromodulators. In this article we review the available data on peptides as central regulators of food ingestion. We stress the possible problems of non-specific effects. We stress that whereas many peptides decrease feeding after central injection, only two families of peptides have been shown to increase feeding after central injection. These are the opioid family and the pancreatic polypeptide-neuropeptide Y family. The putative role of corticotropin releasing factor as the mediator of norepinephrine and serotonin effects on feeding is discussed.

Peptides and feeding

This report reviews the hypothesis that peptides play a role in appetite modulation, stressing that the available evidence is predominantly pharmacological and thus caution needs to be taken in assigning physiological significance at this time. Two peptide systems have been postulated--a peripheral satiety system, typified by the gastrointestinal hormone cholecystokinin and a central feeding system driven by the opioid peptides and neuropeptide Y. This review also discusses the putative role of peptides in the anorexia of aging, drinking elicited by feeding and as mediators of the autonomic effects seen in association with ventromedial hypothalamic lesions.

Antagonism of diazepam-induced feeding in rats by antisera to opioid peptides

Diazepam-induced feeding in rats is antagonized not only by the opiate antagonist naloxone but also intraventricular administration of specific antisera to the endogenous opioid peptides met-enkephalin or beta-endorphin. Pituitary beta-endorphin is probably not implicated in the diazepam effect since blockade with the glucocorticoid dexamethasone of the release of beta-endorphin from the anterior pituitary does not modify the diazepam-induced feeding, which is however prevented by TRH, a suggested physiological antagonist of some of the effects of opioid peptides. The possible central participation of both beta-endorphin and met-enkephalin in the ingestive behavior induced by diazepam gives further support to the postulated physiological role of endogenous opioids in appetite regulation.

The inhibition of tail-pinch-induced food intake by cholecystokinin octapeptides and their fragments

The effects of intraperitoneally (ip.) and intracerebroventricularly (icv.) administered sulfated and nonsulfated cholecystokinin octapeptide (CCK-8-SE and CCK-8-NS) and their N- and C-terminal fragments on the tail-pinch-induced feeding behavior of rats were investigated. After ip. administration, only CCK-8-SE inhibited tail-pinch-induced food intake. After icv. administration, both CCK-8-SE and CCK-8-NS, in doses of 800 pmole/rat, reduced the amount of food eaten. Of the CCK fragments tested icv., the sulfated N-terminal fragments, the middle portion of the CCK-8-sequence (the CCK-3-6 fragment), and the C-terminal tetrapeptide depressed the food intake of rats during tail-pinch, whereas the C-terminal tripeptide significantly increased it. The results suggest that CCK peptides inhibit tail-pinch-induced feeding by separate mechanisms, depending on the route of administration.

Effects of analogs of (pyro)Glu-His-Gly-OH on food consumption and gastric acid secretion in rats

The effects of administration of (pyro)Glu-His-Gly-OH and its analogs on food consumption and 2-Deoxy-D-Glucose (2-DG)-induced gastric acid secretion were examined in rats. (Pyro)Glu-His-Gly-OH and (pyro)Glu-His-EA significantly reduced food consumption, but not gastric acid secretion as compared with controls. The tripeptides: (pyro)Glu-3Me-His-Gly-OH, (pyro)Glu-His-D-Ala-OH, and (pyro)Glu-Phe-Gly-OH were found to significantly inhibit 2-DG-induced gastric acid secretion. Our results indicate that some analogs of (pyro)Glu-His-Gly-OH cause a greater inhibition of food consumption or gastric acid secretion in rats than the original tripeptide, in analogy to findings obtained in dogs.

Zinc deficiency and anorexia in rats: the effect of central administration of norepinephrine, muscimol and bromerogocryptine

Anorexia is a major manifestation of zinc deficiency, but the mechanism(s) for this anorexia are not well defined. In this study we investigated the effects of three modulators of feeding response on the food consumption of zinc deficient rats. Zinc deficient rats showed partial resistance to norepinephrine, eating significantly less at the 20 micrograms dose than the zinc sufficient ad lib controls, and food ingestion could not be induced at the 10 micrograms dose. Similarly, higher doses of the GABA agonist, muscimol, were required to induce feeding in the zinc deficient animals compared to the zinc sufficient controls. The dopamine agonist, bromergocryptine, failed to induce feeding in the zinc deficient animals. These findings are compatible with the concept that zinc deficiency produces a generalized decrease in receptor responsibility, possibly secondary to alterations in membrane fluidity.

The role of the endogenous opiates in zinc deficiency anorexia

Anorexia is a major symptom of zinc deficiency, but the mechanism(s) for this anorexia are poorly defined. Recent studies have suggested an integral role for endogenous opiate peptides in appetite regulation. Dynorphin, a leucine-enkephalin containing opiate peptide, is a potent inducer of spontaneous feeding. In this study we showed that zinc deficient animals were relatively resistant to dynorphin-induced feeding. Measurement of dynorphin levels using a highly sensitive radioimmunoassay showed that zinc deficient animals had lower levels of dynorphin in the hypothalamus than did ad lib fed animals, with weight restricted animals having intermediate values. [3H]-naloxone binding was significantly increased to isolated brain membranes from zinc deficient animals using 1 nM unlabeled naloxone when compared to ad lib fed controls with the weight restricted animals again having intermediate values. These data suggest that abnormalities in endogenous opiate regulation of appetite may well play a role in the anorexia of zinc deficiency. The effects of zinc deficiency on endogenous opiate action appear to include alterations in receptor affinity, a post-receptor defect and alterations in the synthesis and/or release of dynorphin.

A comparison of the effects of corticotropin releasing factor and sauvagine on food intake

Corticotropin releasing factor (CRF) and sauvagine (SVG) when administered ICV both reduced spontaneous feeding as well as feeding induced by deprivation or the administration of ethylketocyclazocine (EKC). For spontaneous- and EKC-induced feeding, SVG produced a larger and longer-lasting suppressive effect than did CRF. Both peptides produced a conditioned taste aversion when paired with a novel saccharin taste. As the feeding effects, SVG produced a stronger aversion than CRF. These studies further establish the similarity between CRF and SVG and suggest that they may have a disruptive effect on feeding.

Involvement of dynorphin and the kappa opioid receptor in feeding

Dynorphin-(1-17) produces a highly specific increase in food ingestion. Similar enhancement of food ingestion is found with dynorphin fragments (1-10), (1-11), (1-13) and (3-13) but not with (1-8) and (1-9). Dynorphin B (rimorphin) also enhances food intake. The highly specific kappa agonist U-50,488 also enhances food intake as do a number of other kappa-opiate receptor agonists. These studies provided further for the role of a highly specific dynorphin-kappa opioid receptor in the modulation of feeding.

The effect of peripherally administered satiety substances on feeding induced by butorphanol tartrate

Endogenous opioid peptides appear to play a role in the initiation of feeding. Butorphanol, an exogenous opiate which preferentially generalizes to the kappa-sigma opiate receptors, is a potent initiator of feeding. In these studies, we examined the effect of peripherally administered putative satiety substances, cholecystokininoctapeptide, somatostatin, bombesin, gastrin-releasing peptide, thyrotropin-releasing hormone, calcitonin and glucagon on butorphanol induced feeding. With the exception of bombesin, all the other putative satiety factors required 2 to 32 times as high a dose to significantly suppress feeding following butorphanol compared to the dosages required to suppress starvation or tail pinch induced feeding. Bombesin appeared to be approximately equipotent in all systems tested. Haloperidol and atropine both suppressed butorphanol induced feeding supporting our previous hypothesis of an integral relationship between acetylcholinergic-dopaminergic and opioid mechanisms in the initiation of feeding. The findings reported here are compatible with an important role for opioid mechanisms in the initiation of feeding.

Effect of intraventricular adenosine on food intake in rats

Previous studies have shown that peripherally administered purines suppress food intake in rats. In this study we show that central administration of adenosine, adenine and AMP potently suppressed food intake in rats. Intraperitoneal adenosine suppressed feeding at the 100 and 50 mg/kg dose whereas 100, 50 and 10 micrograms of intraventricular adenosine suppressed feeding after intracerebroventricular injection at 30 minutes and up to 120 minutes at the high doses. Inosine, 2-deoxyinosine, 7-methyl-inosine and 2-deoxyguanosine all failed to suppress food intake when given intraventricularly at the same doses used for adenosine, adenine and AMP. Adenosine, 10 micrograms ICV, also decreases water uptake. The effect of adenosine was specific for ingestive behaviors as it did not significantly decrease spontaneous movement or grooming. These results suggest that adenosine suppresses feeding via a central mechanism and that this suppressive effect is not dependent on deamination of adenosine to inosine. The central adenosine effect appears to work by a different mechanism to the satiety effect of peripherally administered inosine.

Opioid modulation of appetite

The discovery of opiate receptors and endogenous opioid peptides within the central nervous system has resulted in a number of speculations concerning the physiological significance of these peptides. In the present article, we review the evidence suggesting a primary role for some of the opioid peptides as regulators of ingestive behavior. In particular, we elaborate a hypothesis in which we suggest that in some species opioid peptides may play a role as a tonic inducer of ingestive behaviors, held in check by a variety of neuropeptides and monoamines. This review explores in detail the role of the opioid peptides as major mediators of the reward system and as a link between reward and feeding behaviors. Finally, a teleological role for opioid peptides in species preservation, which may explain the discrepancies in the role of the opioid peptides in feeding behavior in different species is proposed. It is suggested that the feeding profile of the animal provides important clues as to whether or not the animal has an opiate-sensitive feeding system. We stress that interactions with ingested nutrients and the milieu interieur provide an important means by which animals modulate the opiate-entrained feeding drives.

Minireview. Stress induced eating

The relationship of oral behaviors to stress has long been recognized both in humans and in wild animals. In the last decade numerous advances have been made in our understanding of stress-induced feeding predominately because of the development of the simple tail-pinch model of stress induced feeding in rats. Present evidence strongly implicates monoamines and the endogenous opioid peptides as well as other neuropeptides as playing a role in the central regulation of stress-induced eating.

Central effects of neuropeptides on ventilation in the rat

We have examined the effects of centrally applied neuropeptides on ventilation (respiratory rate, tidal volume, and minute ventilation) in urethane-anesthetized rats. TRH caused an increase in respiratory rate, a decrease in tidal volume, but an increase in net minute ventilation. One TRH metabolite, acid TRH, caused similar changes, but no effect was observed from the other TRH metabolite, cHis-Pro. Both bombesin and calcitonin caused increases in minute ventilation due to increases in respiratory rate and tidal volume. Additionally, bombesin induced periodic sighing respirations at rates up to 15/minute which was observed with no other neuropeptide. Substance P, somatostatin, and neurotensin had no effect upon ventilation variables.

Influence of dopamine receptor agonists on gastric acid secretion induced by intraventricular administration of thyrotropin-releasing hormone in the perfused stomach of anaesthetized rats

1 The influence of dopamine receptor agonists on gastric acid secretion stimulated by thyrotropin-releasing hormone (TRH) was studied in the perfused stomach of anaesthetized rats. 2 Intraventricular TRH produced a dose-dependent stimulation of basal gastric acid secretion. 3 Pretreatment with apomorphine, bromocriptine or methamphetamine inhibited the TRH-stimulated gastric acid secretion; these drugs did not influence bethanechol-induced acid secretion. 4 Haloperidol and metoclopramide prevented the antisecretory effects of apomorphine, bromocriptine and methamphetamine. 5 The present study suggests that central dopamine receptor stimulation inhibits intraventricular TRH-induced gastric acid secretion in rats.

Interactions of thyrotropin releasing hormone, its metabolites and analogues with endogenous and exogenous opiates

The interactions of thyrotropin releasing hormone, its metabolites and synthetic analogues with acute and chronic effects of endogenous and exogenous opiates have been described. The endogenous and exogenous opiates are represented by beta-endorphin and morphine, respectively. The pharmacological effects of opiates include analgesia, temperature effects, respiratory depression, catalepsy, locomotor activity, opiate receptor binding, tolerance, and physical dependence. Thyrotropin releasing hormone and related compounds appear to (a) antagonize hypothermia, respiratory depression, locomotor depression and catalepsy but not the analgesia induced by opiates, (b) inhibit the development of tolerance to the analgesic effect but not to the hypothermic effect of opiates, (c) inhibit the development of physical dependence on opiates as evidenced by the inhibition of development of certain withdrawal symptoms, and (d) suppress the abstinence syndrome in opiate dependent rodents. Thyrotropin releasing hormone does not interact with the opiate receptors in the brain. Potential therapeutic applications of thyrotropin releasing hormone and its synthetic analogues in counteracting some of the undesirable effects of opiates are discussed.

The effects of stress on central nervous system concentrations of the opioid peptide, dynorphin

Dynorphin is an opioid peptide distributed throughout the central nervous system. Using a highly specific and sensitive radioimmunoassay for dynorphin we have examined the effect of stress on ir-dynorphin levels in the cortex and hypothalamus of the rat. Stresses related to food ingestion, i.e. starvation (72 hr), mild tail-pinch and insulin (10 U/kg) induced hypoglycemia all produced alterations in ir-dynorphin levels in the cortex. In contrast, restraint stress and 10-minute swim stress produced no changes in ir-dynorphin levels in either the hypothalamus or the cortex. Two hour exposure at 4 degrees C resulted in a fall in ir-dynorphin levels in the hypothalamus. Taken together with previously reported pharmacological effects of dynorphin-(1-13), these results suggest a possible physiological role for dynorphin in appetite and temperature regulation.